Monte Carlo Study of Mixed-Spin S=(1/2,1) Ising Ferrimagnets

We investigate Ising ferrimagnets on square and simple-cubic lattices with exchange couplings between spins of values S=1/2 and S=1 on neighbouring sites and an additional single-site anisotropy term on the S=1 sites. Based mainly on a careful and comprehensive Monte Carlo study, we conclude that there is no tricritical point in the two--dimensional case, in contradiction to mean-field predictions and recent series results. However, evidence for a tricritical point is found in the three-dimensional case. In addition, a line of compensation points is found for the simple-cubic, but not for the square lattice.Comment: 14 pages, 11 figure

Linear independence of localized magnon states

At the magnetic saturation field, certain frustrated lattices have a class of states known as "localized multi-magnon states" as exact ground states. The number of these states scales exponentially with the number $N$ of spins and hence they have a finite entropy also in the thermodynamic limit $N\to \infty$ provided they are sufficiently linearly independent. In this article we present rigorous results concerning the linear dependence or independence of localized magnon states and investigate special examples. For large classes of spin lattices including what we called the orthogonal type and the isolated type as well as the kagom\'{e}, the checkerboard and the star lattice we have proven linear independence of all localized multi-magnon states. On the other hand the pyrochlore lattice provides an example of a spin lattice having localized multi-magnon states with considerable linear dependence.Comment: 23 pages, 6 figure

Existence of the magnetization plateau in a class of exactly solvable Ising-Heisenberg chains

The mapping transformation technique is applied to obtain exact results for the spin-1/2 and spin-S (S=1/2,1) Ising-Heisenberg antiferromagnetic chain in the presence of an external magnetic field. Within this scheme, a field-induced first-order metamagnetic transition resulting in multiplateau magnetization curves, is investigated in detail. It is found that the scenario of the plateau formation depends fundamentally on the ratio between Ising and Heisenbrg interaction constants, as well as on the anisotropy strength of the XXZ Heisenberg interaction.Comment: 16 pages, 10 figures, submitted to J. Phys: Condens. Matte

Analysis of Microsatellite Polymorphism in Inbred Knockout Mice

Previously, we found that the genotype of 42 out of 198 mouse microsatellite loci, which are distributed among all chromosomes except the Y chromosome, changed from monomorphism to polymorphism (CMP) in a genetically modified inbred mouse strain. In this study, we further examined whether CMP also relates to the homologous recombination in gene knockout (KO) mouse strains. The same 42 microsatellite loci were analyzed by polymerase chain reaction (PCR) in 29 KO inbred mouse strains via short tandem sequence repeat (STR) scanning and direct sequence cloning to justify microsatellite polymorphisms. The C57BL/6J and 129 mouse strains, from which these 29 KO mice were derived, were chosen as the background controls. The results indicated that 10 out of 42 (23.8%) loci showed CMP in some of these mouse strains. Except for the trinucleotide repeat locus of D3Mit22, which had microsatellite CMP in strain number 9, the core sequences of the remaining 41 loci were dinucleotide repeats, and 9 out of 41 (21.95%) showed CMPs among detected mouse strains. However, 11 out of 29 (37.9%) KO mice strains were recognized as having CMPs. The popular dinucleotide motifs in CMP were (TG)n (50%, 2/4), followed by (GT)n (27.27%, 3/11) and (CA)n (23.08%, 3/13). The microsatellite CMP in (CT)n and (AG)n repeats were 20% (1/5). According to cloning sequencing results, 6 KO mouse strains showed insertions of nucleotides whereas 1 showed a deletion. Furthermore, 2 loci (D13Mit3 and D14Mit102) revealed CMP in 2 strains, and mouse strain number 9 showed CMPs in two loci (D3Mit22 and D13Mit3) simultaneously. Collectively, these results indicated that microsatellite polymorphisms were present in the examined inbred KO mice

Characterization of New Substrates Targeted By Yersinia Tyrosine Phosphatase YopH

YopH is an exceptionally active tyrosine phosphatase that is essential for virulence of Yersinia pestis, the bacterium causing plague. YopH breaks down signal transduction mechanisms in immune cells and inhibits the immune response. Only a few substrates for YopH have been characterized so far, for instance p130Cas and Fyb, but in view of YopH potency and the great number of proteins involved in signalling pathways it is quite likely that more proteins are substrates of this phosphatase. In this respect, we show here YopH interaction with several proteins not shown before, such as Gab1, Gab2, p85, and Vav and analyse the domains of YopH involved in these interactions. Furthermore, we show that Gab1, Gab2 and Vav are not dephosphorylated by YopH, in contrast to Fyb, Lck, or p85, which are readily dephosphorylated by the phosphatase. These data suggests that YopH might exert its actions by interacting with adaptors involved in signal transduction pathways, what allows the phosphatase to reach and dephosphorylate its susbstrates

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)